Both IDH1/2 mutations are more or less solely connected with glial-type phenotype of brain tumors and are detected in around 5% of primary and approximately 50% of secondary GBM that has been substantiated to confer an improved prognosis [10–12]. Here, IDH1 is linked to glioblastoma.